Survey on Epidemiology of Hypoparathyroidism in France
ConditionHypoparathyroidism
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorEuropean Georges Pompidou Hospital
About this trial
Very few data has been published on the epidemiology of hypoparathyroidism worldwide: none exists specifically for France. Hypoparathyroidism could led to complications. Here, the investigators plan to collect data about both epidemiology, medication and complication of hypoparathyroidism in France.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
patient fro whom chronic hypoparathyroidism is diagnosed
patient living in France
Disqualifiers
patient who does not want his data to be collected in this registry
pseudo-hypoparathyroidism
acute hypoparathyroidism
Trial population
All patients for whom hypoparathyroidism is diagnosed in France
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
No intervention
Other interventionNo intervention
Treatment groups
3,000 Participants
are divided into 1 treatment groupGroup A: Hypoparathyroidism1 intervention
Trial outcomes
Primary outcomes
1
Assessment of the epidemiology of patients with hypoparathyroidism in France
Data collected by questionnaire about etiology of hypoparathyroidism, filled by physicians from clinic folders
Time frame
Through study completion, about 2 yearsSecondary outcomes
1
Assessment of the biology at inclusion will describe the evolution of the included population from diagnosis to now (inclusion)
Number of patients with at least one anomaly at biology (calcemia in mM, calciuria in mmol/j, parathormone in pg/ml, creatininemia in µM, phosphatemia in mM, vitamin D in nmol/l \& magnesemia in mM) at inclusion
Time frame
At inclusion (under treatment): through study completion, about 2 years2
Assessment of the management at inclusion will describe treatment and complications at inclusion
Number of patients with clinical outcomes (complications such as cataract, nephrolithiasis, nephrocalcinosis, and others) and their management at inclusion
Time frame
At inclusion (under treatment): through study completion, about 2 years3
Assessment of the biology (calcemia, calciuria, parathormone, creatininemia, phosphatemia & magnesemia) at diagnosis and drug therapy at inclusion will describe population
Number of patients with at least one anomaly at biology (calcemia in mM, calciuria in mmol/j, parathormone in pg/ml, creatininemia in µM, phosphatemia in mM, vitamin D in nmol/l \& magnesemia in mM) at diagnosis
Time frame
Through study completion, about 2 yearsOther outcomes
1
Assessment of the physician's management will help describing the habits of french physician who manage hypoparathyroidism in terms of follow-up
Data on habits of included physicians about their management of patients with hypoparathyroidism: frequency of complications' follow-up (nephrocalcinosis, cataract, nephrolithiasis and other calcifications) in terms of radiology (CT-scan, echotomography, radiography) and biology (calcium in mM, phosphate in mM, parathormone in pg/ml, magnesium in mM, vitamin D in nmol/l and creatininemia in µM).
Time frame
At inclusionSponsors and contacts
Click on the lead sponsor to view all of their trials.
European Georges Pompidou Hospital
Lead sponsor
Oscar - Filière Santé Maladies Rares
Collaborator
Source ClinicalTrials.gov